Regulation of PAR-1 in patients undergoing percutaneous coronary intervention: Effects of unfractionated heparin and bivalirudin

European Heart Journal

Volumn 30, Issue 15, 2009, Pages 1831-1836

  Eslam, Roza Badr ^a   Reiter, Nina ^b   Kaider, Alexandra ^c   Eichinger, Sabine ^d   Lang, Irene M ^b   Panzer, Simon ^b  

^a Division of Cardiology   (Taiwan)

^b Department of Blood Group Serology and Transfusion Medicine   (Austria)

^c Section of Clinical Biometrics   (Austria)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Bivalirudin; Heparin; PAR 1; Percutaneous coronary intervention; Platelets; Thrombin

Indexed keywords

HEPARIN; HEPARIN IMMUNO; HIRULOG; PADGEM PROTEIN; PROTEINASE ACTIVATED RECEPTOR 1; THROMBIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLEEDING; CONTROLLED STUDY; FEMALE; HUMAN; IN VIVO STUDY; INTERNALIZATION; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; REGULATORY MECHANISM; THROMBOCYTE ACTIVATION;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HEPARIN; HIRUDINS; HUMANS; MALE; MIDDLE AGED; P-SELECTIN; PEPTIDE FRAGMENTS; PLATELET ACTIVATION; RECEPTOR, PAR-1; RECOMBINANT PROTEINS; THROMBIN;

EID: 68749105899     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehp186     Document Type: Article

References (21)

1. Kahn ML, Nakanishi-Matsui M, Shapiro MJ, Ishihara H, Coughlin SR. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest 1999: 103:879-887.
2. Leger AJ, Covic L, Kuliopulos A. Protease-activated receptors in cardiovascular diseases. Circulation 2006: 114:1070-1077.
3. Dormann D, Clemetson KJ, Kehrel BE. The GPIb thrombin-binding site is essential for thrombin-induced platelet procoagulant activity. Blood 2000: 96:2469-2478.
4. Soslau G, Class R, Morgan DA, Foster C, Lord ST, Marchese P, Ruggeri ZM. Unique pathway of thrombin-induced platelet aggregation mediated by glyco-protein Ib. J Biol Chem 2001: 276:21173-21183.
5. Adam F, Guillin MC, Jandrot-Perrus M. Glycoprotein Ib-mediated platelet activation. A signalling pathway triggered by thrombin. Eur J Biochem 2003: 270: 2959-2970.
6. Jurk K, Jahn UR, Van Aken H, Schriek C, Droste DW, Ritter MA, Bernd Ringelstein E, Kehrel BE. Platelets in patients with acute ischemic stroke are exhausted and refractory to thrombin, due to cleavage of the seven-transmembrane thrombin receptor (PAR-1). Thromb Haemost 2004: 91:334-344.
7. Yano Y, Ohmori T, Hoshide S, Madoiwa S, Yamamoto K, Katsuki T, Mitsuhashi T, Mimuro J, Shimada K, Kario K, Sakata Y Determinants of thrombin generation, fibrinolytic activity, and endothelial dysfunction in patients on dual antiplatelet therapy: involvement of factors other than platelet aggregability in Virchow's triad. Eur Heart J 2008: 29:1729-1738.
8. Warkentin TE, Greinacher A, Koster A. Bivalirudin. Thromb Haemost 2008; 99: 830-839.
9. Panes O, Matus V, Saez CG, Quiroga T, Pereira J, Mezzano D. Human platelets synthesize and express functional tissue factor. Blood 2007: 109:5242-5250.
10. Xiao Z, Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 1998: 97:251-256.
11. Schneider DJ, Keating F, Sobel BE. Greater inhibitory effects of bivalirudin compared with unfractionated heparin plus eptifibitide on thrombin-induced platelet activation. Coron Artery Dis 2006: 17:471-476.
12. Keating FK, Dauerman HL, Whitaker DA, Sobel BE, Schneider DJ. Increased expression of platelet P-selectin and formation of platelet-leukocyte aggregates in blood from patients treated with unfractionated heparin plus eptifibatide compared with bivalirudin. Thromb Res 2006: 118:361-369.
13. Harding SA, Din JN, Sarma J, Josephs DH, Fox KA, Newby DE. Promotion of proinflammatory interactions between platelets and monocytes by unfractionated heparin. Heart 2006: 92:1635-1638.
14. Anand SX, Kim MC, Kamran M, Sharma SK, Kini AS, Fareed J, Hoppensteadt DA, Carbon F, Cavusoglu E, Varon D, Viles-Gonzalez JF, Badimon JJ, Marmur JD. Comparison of platelet function and morphology in patients undergoing percutaneous coronary intervention receiving bivalirudin versus unfractionated heparin versus clopidogrel pretreatment and bivalirudin. Am J Cardiol 2007: 100:417-424.
15. Reiter R, Derhaschnig U, Spiel A, Keen P, Cardona F, Mayr FJilma B. Regulation of protease-activated receptor 1 (PAR1) on platelets and responsiveness to thrombin receptor activating peptide (TRAP) during systemic inflammation in humans. Thromb Haemost 2003: 90:898-903.
16. Lincoff AM, BittIJA, Harrington RA, Feit F, Kleiman NS, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Kereiakes DJ, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ, REPLACE-2 Investigators. Bivalirudin and provisional glycoprotein lib/Ilia blockade compared with heparin and planned glycoprotein llb/llla blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003: 289:853-863.
17. Stone GW, White HD, Ohman EM, Bertrand ME, Lincoff AM, McLaurin BT, Cox DA, Pocock SJ, Ware JH, Feit F, Colombo A, Manoukian SV, Lansky AJ, Mehran R, Moses JW, Acute Catheterization Urgent Intervention Triage strategy (ACUITY) trial investigators. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet 2007: 369:907-919.
18. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Kirtane AJ, Parise H, Mehran R, HORIZONS-AMI Trial Investigators. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008: 358: 2218-2230.
19. White HD, Chew DP, Hoekstra JW, Miller CD, Pollack CV Jr, Feit F, Lincoff AM, Bertrand M, Pocock S, Ware J, Ohman EM, Mehran R, Stone GW. Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J Am Coll Cardiol 2008: 51:1734-1741.
20. Kastrati A, Neumann FJ, Mehilli J, Byrne RA, lijima R, Buttner HJ, Khattab AA, Schulz S, Blankenship JC, Pache J, Minners J, Seyfarth M, Graf I, Skelding KA, Dirschinger J, Richardt G, Berger PB, Schomig A, ISAR-REACT 3 Trial Investigators. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med 2008: 359:688-696.
21. Sibbing D, Busch G, Braun S, Jawansky S, Schomig A, Kastrati A, Ott I, von Beckerath N. Impact of bivalirudin or unfractionated heparin on platelet aggregation in patients pretreated with 600 mg clopidogrel undergoing elective percutaneous coronary intervention. Eur Heart J 2008: 29:1504-1509.